GlassScriptPhysician profile
Randall William Johnson
NPI 1295821577
$24,745.01
in general payments reported to CMS, 2019-2025
37 companies · $4,699 in 2025
The $4,699 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,676 · 2020: $3,271 · 2021: $3,080 · 2022: $3,262 · 2023: $3,590 · 2024: $3,168 · 2025: $4,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $929 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,519.10 |
| Travel and Lodging | $929.07 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,456.99 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $3,685.07 | 2019-2025 | |
| Janssen Biotech, INC. | $2,423.43 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,839.32 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,613.96 | 2019-2025 | |
| Lilly USA, LLC | $1,316.59 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $1,284.37 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $1,203.73 | 2019-2025 | |
| Arthrex, INC. | $1,063.59 | 2024-2025 | |
| Horizon Therapeutics Plc | $767.30 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $581.09 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $529.68 | 2019-2025 | Actemra |
| Astrazeneca Pharmaceuticals LP | $523.44 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $450.81 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.71 | 2019-2024 | Cyltezo, Ofev |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $290.99 | 2019-2021 | |
| Johnson & Johnson Health Care Systems INC. | $230.52 | 2023 | Tremfya |
| Tersera Therapeutics LLC | $229.10 | 2022-2023 | Quzyttir |
| Sobi, INC | $196.69 | 2020-2025 | |
| Celgene Corporation | $138.58 | 2019 | |
| Boston Scientific Corporation | $108.65 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $68.44 | 2023 | Lupkynis |
| Antares Pharma, INC. | $61.29 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $58.20 | 2019-2021 | |
| Medexus Pharma, INC. | $42.94 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $39.13 | 2021 | |
| Alexion Pharmaceuticals, INC. | $36.88 | 2021 | |
| Sandoz INC. | $30.29 | 2025 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $28.20 | 2023 | Opsumit, Uptravi |
| Organon LLC | $23.84 | 2022 | |
| Assertio Therapeutics, INC. | $16.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.88 | 2022 | |
| Almatica Pharma LLC | $16.72 | 2025 | Teriparatide |
| Teva Pharmaceuticals USA, INC. | $16.54 | 2024 | Simlandi |
| Arbor Pharmaceuticals, INC. | $16.19 | 2021 | |
| Depuy Synthes Sales INC. | $13.07 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.